![](https://endpts.com/wp-content/uploads/2022/01/AP_17026450572413-scaled.jpg)
Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
Amid aprocitentan’s regulatory review, Idorsia is buying back the hypertension drug from J&J in $350M deal
Johnson & Johnson’s Janssen is handing back the global development and commercialization rights to the hypertension candidate aprocitentan to Idorsia. This …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.